Results 81 to 90 of about 6,848 (153)

Impact of cladribine tablets on PROs in patients with MS: insights from the 1st interim analysis of the CLADFIT-MS study. [PDF]

Front Neurol
Borriello G, Chisari CG, Maimone D, Matta F, Mirabella M, Paolicelli D, Assogna F, Caradonna S, Patti F.   +8 more
europepmc   +1 more source

Compound Library Screening Identified Cladribine as a Novel Radiosensitizer for Prostate Cancer. [PDF]

Cancer Sci
Oka T, Hatano K, Katsuki S, Kanaki T, Inoguchi S, Tani M, Yoshimura A, Horibe Y, Liu Y, Sassi N, Okuda Y, Yamamoto A, Uemura T, Yamamichi G, Ishizuya Y, Hayashi T, Yamamoto Y, Kato T, Kawashima A, Tamari K, Lin B, Tani A, Tsujikawa K, Takahashi Y, Ogawa K, Lupold SE, Nonomura N.   +26 more
europepmc   +1 more source

Cost-effectiveness of treatment sequences following first-line rituximab in relapsing-remitting multiple sclerosis: a Norwegian microsimulation study. [PDF]

Front Neurol
Huygens S, Versteegh M, Berg-Hansen P, Bjelland SH, Holmøy T, Torkildsen Ø.   +5 more
europepmc   +1 more source

Confined B-Cell Reconstruction and High T-Cell Clonality Define Clinical Response to Cladribine Treatment. [PDF]

Ann Neurol
Schneider-Hohendorf T, Eveslage M, Wirth T, Wünsch C, Schumann EM, Lünemann JD, Wiendl H, Klotz L, Schwab N.   +8 more
europepmc   +1 more source

Summary of Research: Pregnancy and Infant Outcomes in Multiple Sclerosis: Findings from the Global MAPLE-MS Pharmacovigilance Program. [PDF]

Neurol Ther
Hellwig K, Tilson HH, Thiel S, Ball K, Seebeck J, Danten M, Dubois N, Sabidó M.   +7 more
europepmc   +1 more source

The effect of cladribine tablets on intrathecal inflammation in relapsing-remitting multiple sclerosis. [PDF]

J Neuroinflammation
Marastoni D, Eccher C, Signori A, Anni D, Foschi M, Crescenzo F, Mazziotti V, Virla F, Sicchieri M, Turano E, Tamanti A, Camera V, Ziccardi S, Zanetti G, Pizzini FB, Martini S, Fratucello A, Bonetti B, Sormani MP, Calabrese M.   +19 more
europepmc   +1 more source

Multi-omics integration provides biological insight and prioritizes potential drug targets in multiple sclerosis progression. [PDF]

J Neuroinflammation
Jiang Y, Xiao J, Kockum I, Stridh P, Liu Q, Olsson T, Alfredsson L, Jiang X.   +7 more
europepmc   +1 more source

Treg Susceptibility to Cladribine-Induced Depletion Correlates With Therapy Response in Patients With Multiple Sclerosis. [PDF]

Neurol Neuroimmunol Neuroinflamm
Cammarata I, Sartori G, Giacomelli T, Pinna V, Pinzon Grimaldos A, De Rosa G, Matarese G, Procaccini C, Mishra D, Di Mitri D, Gasperini C, Guerrera G, Sambucci M, Battistini L, Piconese S.   +14 more
europepmc   +1 more source

Indeterminate cell histiocytosis with ETV3::NCOA2 fusion detected by optical genome mapping. [PDF]

An Bras Dermatol
Mansilla-Polo M, Andreu-Lapiedra R, Valle IL, Such-Taboada E, Évole-Buselli M.   +4 more
europepmc   +1 more source

Cladribine Preserves Normal Central Nervous System Cellular Activity and Promotes Neuroprotection to Oxidative Stress Damage. [PDF]

Int J Mol Sci
Eixarch H, Calvo-Barreiro L, Fissolo N, Boschert U, Hervera A, Comabella M, Montalban X, Espejo C.   +7 more
europepmc   +1 more source